| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A multi-cancer detection test: focus on the positive predictive value
|
Fiala, C.
|
|
|
31 |
9 |
p. 1267-1268
|
artikel
|
| 2 |
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
|
Nakamura, Y.
|
|
|
31 |
9 |
p. 1198-1206
|
artikel
|
| 3 |
Aspirin to prevent gastrointestinal cancer – but recent trial data do not fit
|
Jacobsen, A.P.
|
|
|
31 |
9 |
p. 1262-1263
|
artikel
|
| 4 |
Characterization of on-target adverse events caused by TRK inhibitor therapy
|
Liu, D.
|
|
|
31 |
9 |
p. 1207-1215
|
artikel
|
| 5 |
Comment on ‘Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA’ by M. C. Liu et al.
|
Taylor, W.C.
|
|
|
31 |
9 |
p. 1266-1267
|
artikel
|
| 6 |
Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’
|
Pagès, F.
|
|
|
31 |
9 |
p. 1276
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
31 |
9 |
p. x
|
artikel
|
| 8 |
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial
|
McMillan, A.K.
|
|
|
31 |
9 |
p. 1251-1259
|
artikel
|
| 9 |
GEP-NET: Knowledge gaps in the recent ESMO Guidelines
|
Jain, A.
|
|
|
31 |
9 |
p. 1260-1261
|
artikel
|
| 10 |
Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?
|
Sharifi, Nima
|
|
|
31 |
9 |
p. 1103-1105
|
artikel
|
| 11 |
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
|
Khalaf, D.J.
|
|
|
31 |
9 |
p. 1186-1197
|
artikel
|
| 12 |
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
|
Barcenas, C.H.
|
|
|
31 |
9 |
p. 1223-1230
|
artikel
|
| 13 |
Patients should be the tipping point of individualizing breast cancer surgery: Commentary on ‘Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges’
|
Heil, J.
|
|
|
31 |
9 |
p. 1264
|
artikel
|
| 14 |
PD-1 blockade in Japanese patients with acral lentiginous melanoma
|
Shoushtari, A.N.
|
|
|
31 |
9 |
p. 1106-1108
|
artikel
|
| 15 |
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
|
Metzger Filho, O.
|
|
|
31 |
9 |
p. 1231-1239
|
artikel
|
| 16 |
Prognostic gene expression signature for high-grade serous ovarian cancer
|
Millstein, J.
|
|
|
31 |
9 |
p. 1240-1250
|
artikel
|
| 17 |
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Parker, C.
|
|
|
31 |
9 |
p. 1119-1134
|
artikel
|
| 18 |
Reaching out beyond first-line treatments in advanced biliary tract cancers
|
Lamarca, A.
|
|
|
31 |
9 |
p. 1099-1102
|
artikel
|
| 19 |
Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)
|
Pentheroudakis, G.
|
|
|
31 |
9 |
p. 1265-1266
|
artikel
|
| 20 |
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial
|
Demols, A.
|
|
|
31 |
9 |
p. 1169-1177
|
artikel
|
| 21 |
Reply to ‘Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?’ by Evesque et al.
|
Holch, J.W.
|
|
|
31 |
9 |
p. 1261-1262
|
artikel
|
| 22 |
Reply to the Letter to the Editor ‘Aspirin to prevent gastrointestinal cancer – but recent trial data don't fit’ by Jacobsen and colleagues
|
Bosetti, C.
|
|
|
31 |
9 |
p. 1263
|
artikel
|
| 23 |
Response to W.C. Taylor, and C. Fiala and E.P. Diamandis
|
Liu, M.C.
|
|
|
31 |
9 |
p. 1268-1270
|
artikel
|
| 24 |
Table of Contents
|
|
|
|
31 |
9 |
p. ii-iv
|
artikel
|
| 25 |
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
|
Mauri, G.
|
|
|
31 |
9 |
p. 1135-1147
|
artikel
|
| 26 |
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
|
Subbiah, V.
|
|
|
31 |
9 |
p. 1115-1118
|
artikel
|
| 27 |
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
|
Prasad, V.
|
|
|
31 |
9 |
p. 1112-1114
|
artikel
|
| 28 |
The forefront of ovarian cancer therapy: update on PARP inhibitors
|
Mirza, M.R.
|
|
|
31 |
9 |
p. 1148-1159
|
artikel
|
| 29 |
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
|
Doms, J.
|
|
|
31 |
9 |
p. 1273-1275
|
artikel
|
| 30 |
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype
|
Lu, C.
|
|
|
31 |
9 |
p. 1178-1185
|
artikel
|
| 31 |
Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer
|
Roda, D.
|
|
|
31 |
9 |
p. 1097-1098
|
artikel
|
| 32 |
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study ✰
|
Van Cutsem, E.
|
|
|
31 |
9 |
p. 1160-1168
|
artikel
|
| 33 |
TRK inhibitors: managing on-target toxicities
|
Lim, J.S.J.
|
|
|
31 |
9 |
p. 1109-1111
|
artikel
|
| 34 |
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
|
Karn, T.
|
|
|
31 |
9 |
p. 1216-1222
|
artikel
|
| 35 |
Unintended on-target chromosomal instability following CRISPR/Cas9 single gene targeting
|
Przewrocka, J.
|
|
|
31 |
9 |
p. 1270-1273
|
artikel
|
Tijdschrift beschrijving